Attached files
| file | filename |
|---|---|
| EX-99.3 - PDF OF FACT SHEET - CHEMBIO DIAGNOSTICS, INC. | factsheet.pdf |
| EX-99.2 - PDF OF INVESTOR PRESENTATION - CHEMBIO DIAGNOSTICS, INC. | investorpresentation.pdf |
| EX-99.2 - INVESTOR PRESENTATION- WORD VERSION - CHEMBIO DIAGNOSTICS, INC. | investorpresentation.htm |
| EX-99.1 - EXHIBIT 99.1 FOR PR - CHEMBIO DIAGNOSTICS, INC. | ex99_1.htm |
| 8-K - FORM 8-K FOR PRESS RELEASE - CHEMBIO DIAGNOSTICS, INC. | form8_k.htm |
Corporate Fact Sheet
November 2016
STOCK INFORMATION (as of November 7, 2016)
Ticker: CEMI
Exchange: Nasdaq
Share Price: $7.00/share
Market Cap: $83.90 Million
CORPORATE HIGHLIGHTS
• Global Provider of High Quality POC Infectious Disease Assays
• Sales in 43 countries
• Patented DPP® (Dual Path Platform) Technology
• Multiple products sold into Latin America and U.S.
|
·
|
Lead Product: DPP® HIV 1/2 Assay for Blood/Oral Fluid
|
|
·
|
FDA Approved & CLIA-Waived
|
Future Pipeline of DPP® POC Assays (currently in internal development)
•HIV-Syphilis Combination Assay (U.S.)
• Malaria Assay
• Ongoing Collaborations and Development Projects for:
|
·
|
Malaria (oral fluid/saliva)
|
|
·
|
Zika
|
|
·
|
Dengue Fever
|
|
·
|
Chikungunya
|
|
·
|
Fever Panel
|
|
·
|
Ebola
|
|
·
|
Traumatic Brain Injury
|
|
·
|
Cancer (specific form)
|
|
·
|
Bovine Tuberculosis
|
COMPANY SNAPSHOT
Chembio Diagnostics, Inc. (NASDAQ: CEMI) develops, manufactures, licenses and markets rapid diagnostic assays in the growing $8.0 billion point-of-care (POC) testing market. In addition to its branded and proprietary HIV assays, which it sells in the U.S. and internationally, the Company has several ongoing collaborations for the development of diagnostic assays for Malaria, Dengue, Zika, Ebola and othr febrile illness, flu immunostatus, brain injury and a specific form of cancer.
Dual Path Platform (DPP®) is Chembio's patented POC technology, which offers significant advantages over lateral-flow technologies, including enhanced sensitivity and the ability to conduct multiple tests from a single sample (multiplexing). DPP® continues to provide Chembio with a growing pipeline of business opportunities for the development and manufacture of new products.
CHEMBIO'S LEAD PRODUCTS
DPP® HIV-Syphilis Assay *available in selected non-U.S. markets
|
o
|
Rapid, multiplex detection of HIV 1, HIV 2 and syphilis using a single sample
|
DPP® HIV 1/2 Assay
|
o
|
Rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices
|
HIV 1/2 STAT-PAK® Assay
|
o
|
Single-use, rapid, visual detection of HIV 1 and HIV 2 antibodies
|
SURE CHECK® HIV 1/2 Assay
|
o
|
Self-contained, single-use collection & testing device
|
(See graphics)
PAGE 2
CHEMBIO'S DPP® DUAL PATH PLATFORM
|
o
|
Patented technology
|
|
o
|
Allows improved sensitivity and specificity compared to lateral flow technology
|
|
o
|
Enables multiple test results via a single blood sample (e.g., HIV-Syphilis Combo Assay)
|
|
o
|
Utilized with DPP® Micro Reader for improved results
|
|
o
|
Offers application within infectious disease and potential for a number of other indications
|
(See graphics)
Sexually Transmitted Diseases
HIV
|
o
|
Approximately 37 million people living with HIV/AIDS worldwide (2015)
|
|
o
|
More than 1.1 million people in the U.S. are living with HIV infection, and approximately 1 in 8 are unaware of their infection
|
SYPHILIS
|
o
|
Approx. 12 million people globally become ill with syphilis annually (2015)
|
|
o
|
From 2005-2013, syphilis cases in the U.S. nearly doubled, from 8,724 to 16,663
|
Fever Diseases
Malaria
|
·
|
Approximately 214 million infections and 438,000 deaths annually (2015)
|
Dengue Fever
|
·
|
Approximately 100 million infections annually with 40% of the world population at risk (2013)
|
Ebola
|
·
|
Approximately 28,000 infections and 11,000 deaths in 2014 – 2015
|
Zika
|
·
|
In February 2016, WHO declared the Zika virus a "public health emergency of international concern," as the virus spread to more than twenty countries.
|
DPP PIPELINE & COLLABOTATORS
Chembio Current Internal Development:
|
o
|
DPP® HIV-Syphilis Assay (U.S. market)
|
|
o
|
DPP® Malaria Assay
|
|
o
|
DPP® Chikungunya Assay
|
Current Development Collaborations
• DPP® Dengue Fever – Undisclosed collaborator
• DPP® Ebola & Febrile Illness – CDC Research Agreement
|
·
|
DPP® Fever Panel – The Paul G. Allen Ebola Program
|
|
·
|
DPP® Malaria OF/Saliva– The Bill and Melina Gates Foundation
|
|
·
|
DPP® Zika Assay – The Paul G. Allen Family Foundation
|
|
·
|
DPP® Zika/Dengue/Chikungunya Assay-HHS/BARDA (option)
|
|
·
|
DPP® Traumatic Brain Injury – Perseus Science Group LLC
|
• DPP® Cancer (a specific form) – Undisclosed collaborator
• Bovid TB Assay- U.S. Department of Agriculture
Tech transfer and Distribution
|
o
|
DPP® technology for Geenius™ HIV 1/2 Confirmatory Assay – Bio Rad
|
|
o
|
DPP® product distribution in Brazil- Oswaldo Cruz Foundation
|
|
o
|
DPP® co-branding and distribution in Brazil- Labtest, Diagnostica SA
|
|
o
|
DPP® tech transfer, manufacture and distribution in Malaysia- RVR
|
SENIOR EXECUTIVE OFFICERS
John J. Sperzel III, Chief Executive Officer
Javan Esfandiari, M.S., Chief Science & Technology Officer
Richard Larkin, CPA, Chief Financial Officer
Sharon Klugewicz, M.S., President, America's Region
Robert Passas, Ph.D, President, EMEA & APAC Regions
|
Chembio Diagnostics, Inc.
|
Investor Relations
|
Company Contact
|
|
3661 Horseblock Road
|
Vida Strategic Partners
|
Susan Norcott
|
|
Medford, NY 11763
|
Stephanie C. Diaz
|
631-924-1135 x125
|
|
Ph. 631-924-1135
|
(415) 675-7401
|
snorcott@chembio.com
|
|
Fax 631-924-2065
|
sdiaz@vidasp.com
|
|
|
www.chembio.com
|
|
|